Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Verve Therapeutics, Inc. VERV NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$15.00
+34.8%

Verve Therapeutics, Inc. (VERV) is a Biotechnology company in the Healthcare sector, currently trading at $11.13. It has a SharesGrow Score of 52/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is VERV = $15 (+34.8% upside).

Financials: revenue is $32M, +340.4%/yr average growth. Net income is $199M (loss), growing at -19.7%/yr. Net profit margin is -614.6% (negative). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $70M against $493M equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 12.65 (strong liquidity). Debt-to-assets is 10.8%. Total assets: $647M.

Analyst outlook: 4 / 13 analysts rate VERV as buy (31%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 52/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).

$15.00
▲ 34.77% Upside
Average Price Target
The 12-month price target for Verve Therapeutics, Inc. is $15.00.

VERV SharesGrow Score Overview

60/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 52/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — VERV

✓
VALUE Pass
90/100
VERV trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $15, implying +34.8% from the current price $11. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
VERV: +340.4%/yr revenue is, -19.7%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet VERV: Debt-to-Equity (D/E) ratio 0.14 (conservative), Current ratio is 12.65 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
52/100
VERV: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 52/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 4 / 13 analysts rate VERV as buy (31%). Analyst consensus target is $15 (+34.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
VERV: Net profit margin is -614.6%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.865-11.405
Volume10.31M
Avg Volume (30D)5.72M
Market Cap$994.04M
Beta (1Y)2.24
Share Statistics
EPS (TTM)-2.36
Shares Outstanding$84.72M
IPO Date2021-06-17
Employees274
CEOSekar Kathiresan
Financial Highlights & Ratios
Revenue (TTM)$32.33M
Gross Profit$32.33M
EBITDA$-221.91M
Net Income$-198.71M
Operating Income$-228.66M
Total Cash$524.28M
Total Debt$69.98M
Net Debt$-102.58M
Total Assets$647.39M
Price / Earnings (P/E)-4.7
Price / Sales (P/S)30.74
Analyst Forecast
1Y Price Target$15.00
Target High$15.00
Target Low$15.00
Upside+34.8%
Rating ConsensusHold
Analysts Covering13
Buy 31% Hold 62% Sell 8%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS92539P1012

Price Chart

Track all markets on TradingView
VERV
Verve Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.87 52WK RANGE 11.41

People Also View

BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 CRSP
CRSP
CRISPR Therapeutics AG
$56.86
+3.70%
 BEAM
BEAM
Beam Therapeutics Inc.
$30.30
+0.40%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
 ADPT
ADPT
Adaptive Biotechnologies Corporation
$14.53
+2.83%
 NTLA
NTLA
Intellia Therapeutics, Inc.
$14.78
+3.65%
 SANA
SANA
Sana Biotechnology, Inc.
$3.48
+8.41%
 LIFE
LIFE
aTyr Pharma, Inc.
$14.69
+2.23%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message